MXPA04005209A - Antagonistas del receptor de adenosina a2a. - Google Patents

Antagonistas del receptor de adenosina a2a.

Info

Publication number
MXPA04005209A
MXPA04005209A MXPA04005209A MXPA04005209A MXPA04005209A MX PA04005209 A MXPA04005209 A MX PA04005209A MX PA04005209 A MXPA04005209 A MX PA04005209A MX PA04005209 A MXPA04005209 A MX PA04005209A MX PA04005209 A MXPA04005209 A MX PA04005209A
Authority
MX
Mexico
Prior art keywords
compound
adenosine
receptor antagonists
solvates
administering
Prior art date
Application number
MXPA04005209A
Other languages
English (en)
Spanish (es)
Inventor
Yan Xia
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA04005209A publication Critical patent/MXPA04005209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MXPA04005209A 2001-11-30 2002-11-26 Antagonistas del receptor de adenosina a2a. MXPA04005209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33434201P 2001-11-30 2001-11-30
PCT/US2002/037710 WO2003048165A1 (en) 2001-11-30 2002-11-26 ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
MXPA04005209A true MXPA04005209A (es) 2004-08-19

Family

ID=23306779

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005209A MXPA04005209A (es) 2001-11-30 2002-11-26 Antagonistas del receptor de adenosina a2a.

Country Status (18)

Country Link
US (1) US6916811B2 (https=)
EP (1) EP1448565B1 (https=)
JP (2) JP4284182B2 (https=)
KR (1) KR20050044593A (https=)
CN (1) CN1692116A (https=)
AR (1) AR037680A1 (https=)
AT (1) ATE453647T1 (https=)
AU (1) AU2002346503A1 (https=)
CA (1) CA2468649C (https=)
DE (1) DE60234951D1 (https=)
ES (1) ES2336435T3 (https=)
HU (1) HUP0402018A3 (https=)
IL (1) IL161716A0 (https=)
MX (1) MXPA04005209A (https=)
PE (1) PE20030665A1 (https=)
TW (1) TW200306837A (https=)
WO (1) WO2003048165A1 (https=)
ZA (1) ZA200404161B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
US6964288B2 (en) * 2001-07-06 2005-11-15 Ksaria Corporation Apparatus and method for automated preparation of an optical fiber
KR100687954B1 (ko) 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
AU2003245380A1 (en) * 2002-05-30 2003-12-19 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
TWI331036B (en) 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2005039506A2 (en) * 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
ES2278353T3 (es) * 2003-10-28 2007-08-01 Schering Corporation Procedimiento para preparar 5-amino-pirazolo-(4,3-e)-1,2,4-triazolo(1,5-c)pirimidinas sustituidas.
CA2550071A1 (en) * 2003-12-19 2005-07-07 Schering Corporation Pharmaceutical compositions
EP2258372B8 (en) * 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
HRP20141047T1 (hr) 2008-08-01 2015-01-02 Eye Therapies Llc Pripravci za sužavanje krvnih žila i metode njihove uporabe
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
JP2022540583A (ja) * 2019-07-17 2022-09-16 テオン セラピューティクス，インク． アデノシンａ２ａ受容体アンタゴニスト及びその使用
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
CN112028891B (zh) 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) * 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) * 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
AU2003245380A1 (en) * 2002-05-30 2003-12-19 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
ATE453647T1 (de) 2010-01-15
IL161716A0 (en) 2004-09-27
HUP0402018A3 (en) 2008-06-30
CA2468649C (en) 2009-03-10
WO2003048165A1 (en) 2003-06-12
JP2005511699A (ja) 2005-04-28
CN1692116A (zh) 2005-11-02
JP2008260776A (ja) 2008-10-30
DE60234951D1 (de) 2010-02-11
US6916811B2 (en) 2005-07-12
JP4284182B2 (ja) 2009-06-24
AU2002346503A1 (en) 2003-06-17
ZA200404161B (en) 2005-11-30
HK1063780A1 (en) 2005-01-14
KR20050044593A (ko) 2005-05-12
HUP0402018A2 (hu) 2005-02-28
AR037680A1 (es) 2004-12-01
CA2468649A1 (en) 2003-06-12
PE20030665A1 (es) 2003-08-08
EP1448565B1 (en) 2009-12-30
US20030212059A1 (en) 2003-11-13
EP1448565A1 (en) 2004-08-25
ES2336435T3 (es) 2010-04-13
TW200306837A (en) 2003-12-01

Similar Documents

Publication Publication Date Title
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
TW200517109A (en) Substituted pyridinones
SE0100568D0 (sv) Compounds
UA83182C2 (en) Compounds effecting glucokinase
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
IL147149A0 (en) Novel diphenyl-piperidine derivate
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
EP1453507A4 (en) SOLUBILIZED TOPOISOMERASE GIFT MEDIUM
IL174678A0 (en) Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist
AU2002364953A8 (en) Topoisomerase poison agents
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
WO2004044174A3 (en) Topoisomerase-targeting agents

Legal Events

Date Code Title Description
FG Grant or registration